Panbela Therapeutics Inc. (PBLA)
OTC PINK OTC PINK Primary Summary
Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Operator Greetings, and welcome to the Panbela Therapeutics Third Quarter 2024 Earnings Call. At this time, all participants are on a listen-only mode and a question-and-answer will follow the formal presentation.
Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants James Carbonara - Hayden, IR Jennifer Simpson - President and Chief Executive Officer Susan Horvath - Vice President and Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone, and welcome to the Panbela Therapeutics Second Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode.
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to investors on Thursday, May 16th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.07) for the quarter, down from their prior estimate of ($1.28). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Panbela Therapeutics’ current full-year earnings is ($8.38) per share. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($2.07) EPS, Q4 2024 earnings at ($1.98) EPS, FY2024 earnings at ($8.38) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($1.01) EPS. Separately, Roth Mkm reissued a “buy” rating on shares of Panbela Therapeutics in a report on Wednesday, March 27th. Read Our Latest Research Report on Panbela Therapeutics Panbela Therapeutics Stock Performance Shares of PBLA stock opened at $0.44 on Monday. The stock’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $5.94. The firm has a market capitalization of $1.53 million, a PE ratio of 0.00 and a beta of 1.55. Panbela Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $243.06. Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($24.34) by ($41.56). About Panbela Therapeutics (Get Free Report) Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. Read More Five stocks we like better than Panbela Therapeutics What Are Growth Stocks and Investing in Them MarketBeat Week in Review – 5/13 – 5/17 What is Forex and How Does it Work? Take-Two Interactive Software Offers 2nd Chance for Investors Using the MarketBeat Dividend Tax Calculator Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Panbela Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JP Joseph Pantginis HC Wainwright & Co. | -664.8 | $7,764.92 | $6.65 | $7,758.27 | 99.91% |
Panbela Therapeutics Inc. (PBLA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Panbela Therapeutics Inc. ever had a stock split?
Panbela Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jennifer K. Simpson CEO | OTC PINK Exchange | 69833W107 CUSIP |
| US Country | 7 Employees | - Last Dividend | 18 Jan 2024 Last Split | 3 Jan 2017 IPO Date |
Overview
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for patients with pressing unmet medical needs. The company dedicates its efforts to discovering treatments that can significantly improve patient outcomes, particularly in the cancer domain. It was originally established as Sun BioPharma, Inc. before transitioning to Panbela Therapeutics, Inc. in December 2020. Since its incorporation in 2011, Panbela Therapeutics has been headquartered in Waconia, Minnesota, marking a decade of commitment to advancing medical research and therapeutic development.
Products and Services
- Ivospemin (SBP-101) - Ivospemin, designated as a proprietary polyamine analogue, represents Panbela Therapeutics’ forefront in its clinical journey with a completion of Phase Ia/Ib clinical trial targeting patients suffering from metastatic pancreatic ductal adenocarcinoma, a particularly aggressive cancer type. The unique mechanism of action focuses on disrupting cancer cell proliferation, offering a new hope in treating this challenging condition.
- Flynpovi - This combination therapy, merging eflornithine (CPP-1X) with sulindac, is presently undergoing a Phase III clinical trial. Flynpovi is designed to leverage the synergistic effects of both drugs to provide an enhanced therapeutic outcome for patients, showcasing Panbela Therapeutics’ commitment to innovative cancer treatment solutions.
- Eflornithine - Serving as an enzyme-activated irreversible inhibitor of ornithine decarboxylase, Eflornithine is under a Phase I/II trial to assess its effectiveness and safety. The product underscores Panbela’s strategic approach in exploring enzyme inhibition as a pathway to curb cancer cell growth, illustrating its broadened scope in oncology research and development.
In support of its visionary goals, Panbela Therapeutics has entered into a strategic research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. This collaboration underlines the company’s dedication to bringing groundbreaking therapies from the laboratory bench to the patient’s bedside, fueled by alliances with leading research institutions.
